- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06241677
Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC (DOAC-IVT)
Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on Direct Oral Anticoagulants - A Prospective Multicenter Study
Direct oral anticoagulants (DOAC) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, rivaroxaban - were associated with lower risks of major bleeding compared to warfarin. Listed as core essential medicines by the World Health Organization, DOAC prescriptions have been surging worldwide. In Hong Kong, approximately 80,000 patients received DOACs from January 2009 through December 2022 according to the Hospital Authority registry.
The widespread DOAC usage had created DOAC-specific clinical dilemmas that lack evidence-based treatment despite twenty years of prescribing experience. Ischemic stroke despite DOAC (IS-DOAC), in particular, may occur in up to 6% of DOAC users annually. Due to the in vivo anticoagulation effect, there had been concerns of intracerebral bleeding (ICH) with intravenous thrombolytic therapy (IVT) for acute IS-DOAC. Under the current guideline recommendations, most acute IS-DOAC are contraindicated to IVT (see Intravenous thrombolytic therapy), which resulted in only a small proportion of acute ISDOAC patients being able to receive IVT even if presented early. Nonetheless, our group found that majority of patients had a DOAC level of <50ng/mL only 24 hours after DOAC cessation (see work done by us), a level deemed clinically negligible and safe for thrombolytic therapy. Together with evolving clinical evidence discussed below, IS-DOAC patients maybe unnecessarily barred from IVT, thus compromised functional recovery.
With robust pharmacokinetic and retrospective clinical evidence to support, it is hypothesized that IVT are safe in IS-DOAC patient. The investigators hereby propose a prospective multicenter study to determine the efficacy and safety of IVT in acute IS-DOAC.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yiu Ming Bonaventure Ip
- Phone Number: +85226352152
- Email: bonaventureip@cuhk.edu.hk
Study Contact Backup
- Name: Trista Hung
- Phone Number: +85226352152
- Email: tristahung@cuhk.edu.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Chinese University of Hong Kong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Acute ischemic stroke patients with a last-known-well to presentation time within 4.5 hours
- Patients who took any doses of apixaban (2.5mg or 5mg twice daily), dabigatran (110mg or 150mg twice daily), edoxaban (30mg or 60mg daily) or rivaroxaban (15mg or 20mg daily) 12-48 hours before presentation
- National Institute of Health Stroke Scale (NIHSS) ≥ 3
- Alberta Stroke Programme Early CT (ASPECT) score ≥ 6
- Pre-morbid modified Rankin Scale (mRS) ≤ 3
- Patients aged ≥ 18 years old
Exclusion Criteria:
- Initial CT brain showing intracranial haemorrhage
- Contraindications to IVT according to current guideline recommendations [5], except for the use of DOAC within 12-48 hours
- Patients with an estimated glomerular filtration rate of ≤ 30ml/min/1.73m2
- Patients with bleeding propensities apart from the use of DOAC, e.g. platelet count of < 100x109/L
- Patients with significant head injury immediately prior to presentation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: IVT group
For patients enrolled into the IVT group from participating centers that allow IVT in patients with last DOAC intake 12-48 hours before presentation (PWH, QEH, QMH, UCH, TMH): Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg, intravenous infusion) or tenecteplase (0.25mg/kg, maximum dosage 25mg, intravenous infusion) will be given at discretion of the treating physician.
|
Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given
Other Names:
|
No Intervention: Control
For patients enrolled into the control group from participating centers that exclude eligible patients from IVT (PMH, PYNEH): no IVT will be given unless specific antidote can be administered before IVT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Rankin Scale (mRS)
Time Frame: 3 months after CVA
|
To measure the degree of disability as a primary efficacy outcome, on the scale of 0-6: 0= no symptoms at all, 6=dead
|
3 months after CVA
|
Presence of symptomatic intracerebral hemorrhage (ICH)
Time Frame: up to 1 year
|
As primary safety outcome.
By the Heidelberg Bleeding Classification, the investigators shall categorize intracranial hemorrhages into HI1, HI2, PH1, PH2, and define symptomatic ICH as blood at any site in the brain with clinical deterioration (e.g.
drowsiness and increased hemiparesis) or an increase in National Institute of Health Stroke Scale (NIHSS) score of ≥ 4 points (scores ranging from 0-42, higher scores indicating greater severity.)
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of asymptomatic ICH
Time Frame: up to 1 year
|
As seen from computer tomography (CT) and magnetic resonance imaging (MRI)
|
up to 1 year
|
Presence of hemorrhagic transformation
Time Frame: up to 1 year
|
As seen from computer tomography (CT) and magnetic resonance imaging (MRI)
|
up to 1 year
|
Presence of malignant cerebral edema
Time Frame: up to 1 year
|
As seen from computer tomography (CT) and magnetic resonance imaging (MRI)
|
up to 1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIRB-2023-167-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CVA (Cerebrovascular Accident)
-
Centre Hospitalier Universitaire DijonCompletedSymptomatic CVA (de Novo CVA)France
-
Universitaire Ziekenhuizen KU LeuvenCompletedTranscranial Direct Current Stimulation | Cerebrovascular Accident (CVA)Belgium
-
University of California, IrvineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingStroke, Ischemic | Cerebrovascular Accident (CVA)United States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation...CompletedStroke | Vascular Accident, Brain | Stroke, Acute | Cerebrovascular Accident | Cerebral Stroke | Cerebrovascular Stroke | Cerebrovascular Accident, Acute | Apoplexy | CVA | Cerebrovascular ApoplexyCanada
-
Parker Hannifin CorporationCedars-Sinai Medical Center; Kessler Foundation; TIRR Memorial Hermann; Shirley... and other collaboratorsCompletedStroke | Hemiplegia | Cerebrovascular Accident (CVA)United States
-
University Hospital, Strasbourg, FranceRecruitingCerebrovascular Accident (CVA)France
-
Beth Israel Deaconess Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS)CompletedStroke | Cerebrovascular Accident | Acute Stroke | Acute Cerebrovascular Accident | Apoplexy | CVAUnited States
-
Toronto Rehabilitation InstituteUniversity of Toronto; Heart and Stroke Foundation of CanadaRecruiting
-
VA Office of Research and DevelopmentActive, not recruitingCVA (Cerebrovascular Accident)United States
-
University of Southern CaliforniaRecruitingCVA (Cerebrovascular Accident)United States
Clinical Trials on alteplase or tenecteplase
-
Centre Hospitalier Sud FrancilienCompletedAcute Anterior Choroidal Infarction (ACI) | Paramedian Pontine Infarction (IPP)France
-
The First Affiliated Hospital of University of...RecruitingBasilar Artery Occlusion | Acute Cerebrovascular Accident | Stroke Due to Basilar Artery OcclusionChina
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
-
Boehringer IngelheimCompleted
-
Centre Hospitalier Sud FrancilienRecruitingAcute Distal Vessel Occlusion StrokeFrance
-
NHS Greater Glasgow and ClydeUniversity of Edinburgh; Oxford University Hospitals NHS Trust; University of...UnknownIschemic StrokeUnited Kingdom
-
University of CalgaryCompletedStroke, Acute | Thromboses, IntracranialCanada
-
Haukeland University HospitalTerminatedCerebrovascular Disorders | Ischemic Stroke | Stroke, AcuteNorway
-
Lars ThomassenThe Research Council of NorwayCompleted
-
Boehringer IngelheimCompleted